Strainsforpains, Inc. Sets the Stage for Massive Growth in the Cannabis Industry and AI Innovation
Strainsforpains (OTC: EBYH) reported significant growth in 2024 with over $300,000 in CBD sales and projects reaching $2 million in sales by end of 2025. The company operates from a 7-acre facility in Pennsylvania, strategically located near Amazon's $650 million AI data center grid.
The company is expanding through multiple initiatives including: new CBD formulations with Australian plum extract, planned collaborations with influencers and athletes, and development of an AI-powered app for healthcare professionals. The company maintains research partnerships with institutions like Harvard, Mt. Sinai, and Johns Hopkins, and has established joint ventures with Cannabis Science Inc., GenBio, and Cannasphere Biotech for drug development and CBD product innovation.
Additional growth plans for 2025 include launching a podcast and TV show across major streaming platforms, and the CEO's upcoming book release on cannabis and pain management in February 2025.
Strainsforpains (OTC: EBYH) ha registrato una crescita significativa nel 2024 con oltre 300.000 dollari di vendite di CBD e prevede di raggiungere 2 milioni di dollari di vendite entro la fine del 2025. L'azienda opera da una struttura di 7 acri in Pennsylvania, situata strategicamente vicino al centro dati AI da 650 milioni di dollari di Amazon.
L'azienda sta espandendo le proprie attività attraverso molteplici iniziative, tra cui: nuove formulazioni di CBD con estratto di prugna australiana, collaborazioni programmate con influencer e atleti, e sviluppo di un'app alimentata da AI per professionisti del settore sanitario. Mantiene partnership di ricerca con istituzioni come Harvard, Mt. Sinai e Johns Hopkins, e ha stabilito joint venture con Cannabis Science Inc., GenBio e Cannasphere Biotech per lo sviluppo di farmaci e innovazione di prodotti a base di CBD.
I piani di crescita aggiuntivi per il 2025 includono il lancio di un podcast e di uno show televisivo su importanti piattaforme di streaming, e l'uscita del libro del CEO sulla cannabis e la gestione del dolore prevista per febbraio 2025.
Strainsforpains (OTC: EBYH) reportó un crecimiento significativo en 2024 con más de 300,000 dólares en ventas de CBD y proyecta alcanzar 2 millones de dólares en ventas para finales de 2025. La compañía opera desde una instalación de 7 acres en Pennsylvania, estratégicamente ubicada cerca de la red de centros de datos de IA de Amazon, que costó 650 millones de dólares.
La empresa se está expandiendo a través de múltiples iniciativas, incluidas: nuevas formulaciones de CBD con extracto de ciruela australiana, colaboraciones planificadas con influencers y atletas, y el desarrollo de una aplicación impulsada por IA para profesionales de la salud. Mantiene asociaciones de investigación con instituciones como Harvard, Mt. Sinai y Johns Hopkins, y ha establecido empresas conjuntas con Cannabis Science Inc., GenBio y Cannasphere Biotech para el desarrollo de medicamentos e innovación de productos de CBD.
Los planes de crecimiento adicionales para 2025 incluyen el lanzamiento de un podcast y un programa de televisión en las principales plataformas de streaming, y la próxima publicación del libro del CEO sobre cannabis y manejo del dolor en febrero de 2025.
Strainsforpains (OTC: EBYH)은 2024년에 30만 달러 이상의 CBD 판매로 знач significativo que 성장했다고 보고하였으며, 2025년 말까지 200만 달러에 도달할 것으로 예상하고 있습니다. 이 회사는 펜실베이니아주에서 7에이커 규모의 시설에서 운영되고 있으며, 아마존의 6억 5천만 달러 규모의 인공지능 데이터 센터와 전략적으로 가깝게 위치해 있습니다.
회사는 호주 자두 추출물로 만든 새로운 CBD 포뮬레이션, 인플루언서와 운동선수와의 협업 계획, 의료 전문가를 위한 인공지능 앱 개발 등 여러 가지 이니셔티브를 통해 확장하고 있습니다. 하버드, 마운트 시나이 및 존스 홉킨스와 같은 기관과 연구 파트너십을 유지하며, Cannabis Science Inc., GenBio 및 Cannasphere Biotech와 의약품 개발 및 CBD 제품 혁신을 위한 합작 회사를 설립했습니다.
2025년 추가 성장 계획에는 주요 스트리밍 플랫폼에서의 팟캐스트 및 TV 쇼 개설, 그리고 2025년 2월에 있을 CEO의 대마초와 통증 관리에 관한 책 출간이 포함되어 있습니다.
Strainsforpains (OTC: EBYH) a rapporté une croissance significative en 2024 avec plus de 300 000 dollars de ventes de CBD et prévoit d'atteindre 2 millions de dollars de ventes d'ici fin 2025. L'entreprise opère à partir d'un site de 7 acres en Pennsylvanie, situé stratégiquement près du centre de données en IA d'Amazon, qui coûte 650 millions de dollars.
L'entreprise s'agrandit grâce à de multiples initiatives, notamment : de nouvelles formulations de CBD avec de l'extrait de prune australienne, des collaborations prévues avec des influenceurs et des athlètes, et le développement d'une application alimentée par l'IA pour les professionnels de la santé. Elle entretient des partenariats de recherche avec des institutions comme Harvard, Mt. Sinai et Johns Hopkins, et a établi des coentreprises avec Cannabis Science Inc., GenBio et Cannasphere Biotech pour le développement de médicaments et l'innovation de produits à base de CBD.
Les plans de croissance supplémentaires pour 2025 incluent le lancement d'un podcast et d'une émission de télévision sur les principales plateformes de streaming, ainsi que la publication à venir du livre du PDG sur le cannabis et la gestion de la douleur en février 2025.
Strainsforpains (OTC: EBYH) meldete 2024 ein signifikantes Wachstum mit über 300.000 Dollar an CBD-Verkäufen und plant, bis Ende 2025 2 Millionen Dollar an Verkäufen zu erreichen. Das Unternehmen betreibt eine 7 Acres große Anlage in Pennsylvania, die strategisch in der Nähe des 650 Millionen Dollar teuren KI-Datenzentrums von Amazon liegt.
Das Unternehmen erweitert seine Aktivitäten durch mehrere Initiativen, darunter: neue CBD-Formulierungen mit australischem Pflaumextrakt, geplante Kooperationen mit Influencern und Sportlern sowie die Entwicklung einer KI-unterstützten App für Gesundheitsfachkräfte. Es unterhält Forschungskooperationen mit Institutionen wie Harvard, Mt. Sinai und Johns Hopkins und hat Joint Ventures mit Cannabis Science Inc., GenBio und Cannasphere Biotech für die Arzneimittelentwicklung und Innovation von CBD-Produkten gegründet.
Zusätzliche Wachstumspläne für 2025 umfassen die Einführung eines Podcasts und einer Fernsehsendung auf großen Streaming-Plattformen sowie die bevorstehende Veröffentlichung des Buches des CEO über Cannabis und Schmerzmanagement im Februar 2025.
- Achieved $300,000 in CBD sales in 2024
- Projects $2 million in CBD sales for 2025
- Strategic location near Amazon's $650 million AI data center
- Multiple research partnerships with major institutions
- Joint ventures with established cannabis/biotech companies
- Current revenue scale is relatively small
- Many initiatives are still in planning phase without proven results
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Strainsforpains, Inc. fka/ E-Buy Home, Inc. (OTC: EBYH). Strainsforpains, Inc. is redefining the future of wellness, cannabis innovation, and AI integration. With a transformative year in the books, the company is poised to disrupt multiple industries and deliver groundbreaking results in 2025.
Unparalleled Revenue Growth and Market Expansion
"2024 was a milestone year," stated CEO Y. Simon Shainberg. "Our revenues far surpassed expectations, with over
Strainsforpains is aggressively expanding its product lines and geographic reach, bringing innovative CBD solutions to a wider audience. New formulations featuring powerful antioxidants like Australian plum extract promise to elevate the company’s reputation as a leader in health and wellness solutions.
A Prime Location for Innovation
Strategically positioned within Amazon’s
Influencer-Driven Marketing and Endorsements
2025 will see Strainsforpains collaborating with high-profile influencers, athletes, and celebrities to bring its products to the forefront of the market. These partnerships will drive brand visibility, credibility, and consumer engagement across global markets.
Pioneering Cannabis Research and AI Integration
Building on over 20 years of research and collaborations with prestigious institutions such as Harvard, Mt. Sinai, and Johns Hopkins, Strainsforpains is at the forefront of cannabinoid science. The company’s proprietary app, powered by advanced AI algorithms, provides real-time data to healthcare professionals, revolutionizing pain management and patient care.
"We’re blending cutting-edge cannabis research with state-of-the-art AI to improve lives and establish ourselves as leaders in both the medical and tech industries," Shainberg added.
Media and Thought Leadership
Strainsforpains is also making waves in the media with plans for a podcast and TV show in 2025. These platforms will feature expert insights, celebrity endorsements, and compelling stories about the transformative power of cannabis. The podcasts will stream on major platforms like Roku, YouTube, Facebook, and Instagram, amplifying the company’s global reach.
Adding to the momentum, Mr. Shainberg’s upcoming book on cannabis and pain management will debut in February 2025, further cementing Strainsforpains as a thought leader in the wellness industry.
Strategic Partnerships for Long-Term Growth
Our company has several high-impact collaborations that will enhance its overall growth. We have a joint venture with Cannabis Science, Inc. on commercialization and drug development for their Harvard studied and patented cancer killing drugs utilizing cannabinoids. We are proud to have established strong partnerships with Virginia and Pennsylvania farmers and distributors ensuring a resilient and optimized supply chain, with products stored both at our 7-acre Pennsylvania facility and our New York City location. We have a licensing arrangement with GenBio, a biotech research company, whose mission is to develop the next generation of anti-inflammatory drugs. We have a project with Cannasphere Biotech, LLC, an Arizona based leading manufacturer of CBD products, to develop water solubility and nanoliposomal cannabinoid products. All our partnerships and agreements are with companies that have robust proprietary intellectual property, expertise in the cannabis space, and have developed industry relationships. These partnerships enhance its supply chain, innovation pipeline, and market presence.
A Visionary Future
Positioned at the crossroads of wellness and technology, Strainsforpains is set to redefine the cannabis and AI landscapes. With bold plans, strategic alliances, and a relentless commitment to innovation, the company is crafting a compelling growth story that investors won’t want to miss.
Stay tuned for upcoming announcements as Strainsforpains continues to break barriers and shape the future of wellness and data-driven healthcare.
Management and Advisory
Mr. Simon Shainberg has over 17 years of cannabis research and studies within the wellness space, including working with Raphael Mechoulam of Tel Aviv, the well known originator of the concept of the cannabinoid system. He has extensive experience in algorithmic methodology, healthcare technology, pain management, artificial intelligence, and mergers and acquisitions. He is a member of the prestigious International Cannabinoid Research Society, https://icrs.com
Dr. Michael Stern is a board certified urologist and urological surgeon. He served on the faculty at Bast-yr University School of Naturopathic Medicine for 11 years ( 1995-2006). Dr. Stern operated the Northwest healthy Options Clinic in Seattle, Washington. He continues to advise patients on lifestyle issues and alternative healthy treatments for a wide variety of diseases, including the use of medical cannabis. He is also known for his diet book “The Rotation Diet”.
Mr. Epstein is based in New York City. He is the President and Founder of Geoval Consulting LLC, a firm that applies geological expertise and experience to evaluate prime target investment opportunities. Geoval utilizes geochemical analytical data and modeling for risk profiling to certify geological assets and property selection for private and public entities. He has over 50 publications, including work on experimental and field biogeochemical reactions in saltwater in respected scientific journals, with a focus on successfully merging geology with economic viability. For over 30 years, Samuel Epstein served as an investment advisor as an SVP for Merrill Lynch and Morgan Stanley. For the past 20 years, serves on the Board of Governors for Touro College and University, and acting as an executive director of the Touro College Center for Environmental and Geological Research.
About Strainsforpains, Inc., (OTC: EBYH) fka/ E-Buy Home Inc.
Strainsforpains is progressing towards completing its Audit to become fully-reporting, change its symbol, creating the revenues and asset base for a NASDAQ Uplisting. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company’s objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. Furthermore, the proprietary app incorporating advanced artificial intelligence, collaborating with pain management departments at hospitals and health care professionals. The app integrates artificial intelligence to expand the selection of cannabis varietals, positioning itself as a leading educational tool for pain management operations at hospitals and with doctors specializing in pain relief. The company owns a 7 acre facility in Pennsylvania. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, https://icrs.co/.
Safe Harbor Statement
Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.’s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets.
For further info and Media Contact: Y. Simon Shainberg, CEO
1-347-218-0844
simon@strainsforpains.com
https://www.strainsforpains.com/
https://www.facebook.com/profile.php?id=100071016855607
https://twitter.com/strainsforpains https://www.instagram.com/strains_for_pains/
https://www.instagram.com/strains_for_pains/
https://www.linkedin.com/company/strainsforpains/?viewAsMember=true
https://audioboom.com/posts/8466160-strainsforpains-inc-discusses-inspiration-apptechnology-and-cbd-market-entrance-with-the-stoc
https://www.youtube.com/watch?v=E-lftNrcFLk
FAQ
What were EBYH's CBD sales in 2024 and what is projected for 2025?
Where is EBYH's main facility located and why is it significant?
What key partnerships does EBYH have for cannabis research and development?
What new products and initiatives is EBYH launching in 2025?
